Osteoporosis following solid organ transplantation

Future Rheumatology

Volumn 2, Issue 4, 2007, Pages 341-345

  Vega, Damaris ^a   Sakhaee, Khashayar ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; STEROID; TACROLIMUS; VITAMIN D;

BONE DENSITY; BONE DISEASE; CHRONIC LIVER DISEASE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EDITORIAL; FRACTURE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERPARATHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

EID: 34547911036     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.4.341     Document Type: Editorial

References (66)

1. Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy N: Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol. Dial. Transplant. 13(5), 1250-1255 (1998).
2. Leidig-Bruckner G, Hosch S, Dodidou P et al.: Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357(9253), 342-347 (2001).
3. Vautour LM, Melton LJ III, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT: Long-term fracture risk following renal transplantation: a population-based study. Osteoporos. Int. 15(2), 160-167 (2004).
4. Ramsey-Goldman R, Dunn JE, Dunlop DD et al.: Increased risk of fracture. in patients receiving solid organ transplants. J. Bone Miner. Res. 14(3), 456-463 (1999).
5. Cohen A, Sambrook P, Shane E: Management of bone loss after organ transplantation. J. Bone Miner. Res. 19(12), 1919-1932 (2004).
6. Maalouf NM. Shane E: Osteoporosis after solid organ transplantation. J. Clin. Endocrinol. Metab. 90(4), 2456-2465 (2005).
7. Suzuki Y, Ichikawa Y, Saito E. Homma M: Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32(2), 151-156 (1983).
8. Sakakura M, Takebe K, Nakagawa S: inhibition of luteinizing hormone secretion induced by synthetic LRH by lonk-term treatment with glucocorticoids in human subjects. J. Clin. Endocrinol. Metab. 40(5). 774-779 (1975).
9. Krueger BA, Trakshel GM. Sluss PM. Maines MD: Cyclosporin-mediated depression of luteinizing hormone receptors and home biosynthesis in rat testes: a possible mechanism for decrease in serum testosterone. Endocrinology 129(5), 2647-2654 (1991).
10. Canalis E, Delany AM: Mechanisms of glucocorticoid action in bone. Ann. NY Acad. Sci. 966, 73-81 (2002).
11. Weinstein RS, Jilka RL, Parfitt AM. Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102(2), 274-282 (1998).
12. Epstein S: Post-transplantation bone disease: the role of immmusuppressive agents and the skeleton. J. Bone Miner. Res. 11(1), 1-7 (1996).
13. Cvetkovic M, Mann GN, Romm DF et al.: The deleterious effects of long-term cyclosporine A. cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57(8), 1231-1237 (1994).
14. Compston JE: Osteoporosis after liver transplantation. Liver Transpl. 9(4), 321-330 (2003).
15. Monegal A, Navasa M, Guanabens; N et al.: Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif. Tissue Int. 60(2), 148-154 (1997).
16. Diez A, Puig J, Serrano S et al.: Alcohol-induced bone disease in the absence of severe chronic liver damage. J. Bone Miner. Res. 9(6), 825-831 (1994).
17. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28(3), 695-699 (1998).
18. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J. Clin. Invest. 95(6), 2581-2586 (1995).
19. Floreani A, Mega A, Tizian L et al.: Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos. Int. 12(9), 749-754 (2001).
20. Compston JE, Thompson RP: Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1(8014), 721-724 (1977).
21. Shane E, Silverberg SJ, Donovan D et al.: Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am. J. Med 101(3), 262-269 (1996).
22. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D: Severe osteoporosis before and after lung transplantation. Chest 109(5), 1176-1183 (1996).
23. Aris RM, Renner JB, Winders AD et al.: Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann. Intern. Med. 128(3), 186-193 (1998).
24. Ionescu AA, Nixon LS, Evans WD et al.: Bone density, body composition, and inflammatory status in cystic fibrosis. Am. J. Respir. Crit. Care Med 162(3 Pt 1), 789-794 (2000).
25. Lark RK, Lester GE, Ontjes DA et al.: Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am. J. Clin. Nutr. 73(3), 602-606 (2001).
26. Haworth CS, Selby PL, Webb AK et al.: Low bone mineral density in adults with cystic fibrosis. Thorax 54(11), 961-967 (1999).
27. Haworth CS, Webb AK, Egan JJ et al.: Bone histomorphometry in adult patients with cystic fibrosis. Chest 118(2), 434-439 (2000).
28. Elkin SL, Vedi S, Bord S, Garrahan NJ, Hodson ME, Compston JE: Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am. J. Respir. Cris. Care Med. 166(11), 1470-1474 (2002).
29. Shane E, Mancini D, Aaronson K et al.: Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am. J. Med. 103(3), 197-207 (1997).
30. Pisani B, Mullen GM: Prevention of osteoporosis in cardiac transplant recipients. Curr. Opin. Cardiol. 17(2), 160-164 (2002).
31. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N. Engl. J. Med. 333(3), 166-174 (1995).
32. Alem AM, Sherrard DJ, Gillen DL et al.: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 58(1), 396-399 (2000).
33. Stehman-Breen CO, Sherrard DJ, Alem AM et al.: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 58(5), 2200-2205 (2000).
34. Pabico RC, McKenna BA: Metabolic problems in renal transplant patients. Persistent hyperparathyroidism and hypophosphatemia: effects of intravenous calcium infusion. Transplant Proc. 20(1 Suppl. 1), 438-442 (1998).
35. Green J, Debby H, Lederer E, Levi M, Zajicek HK, Bick T: Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int. 60(3), 1182-1196 (2001).
36. Rosenbaum RW, Hruska KA, Korkor A, Anderson C, Slatopolsky E: Decreased phosphate reabsorption after renal transplantation: evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int. 19(4), 568-578 (1981).
37. Jonsson KB: The role of fibroblast growth factor 23 in renal disease. Nephrol. Dial. Transplant. 20(3), 479-482 (2005).
38. Bhan I, Shah A, Holmes J et al.: Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int. 70(8), 1486-1494 (2006).
39. Ghanekar H, Moe OW, Sakhaee K: Post renal transplantation hypophosphatemia: natural history and pathogenesis. Am. J. Transplant. 7(5) 1193-1200 (2007).
40. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J. Bone Miner. Res. 17(12), 2094-2105 (2002).
41. Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81(10), 3441-3447 (1996).
42. Martin KJ, Olgaard K, Coburn JW et al.: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am. J. kidney Dis. 43(3), 558-565 (2004).
43. Cueto-Manzano AM, Konel S, Crowley V et al.: Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 75(12), 2053-2058 (2003).
44. Ponticelli C, Aroldi A: Osteoporosis after organ transplantation. Lancet 357(9268), 1623 (2001).
45. Groez W, Mundinger A, Gugel B, Exner V, Reichelt A, Schollmeyer P: Mixing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant. Proc. 24(5), 2652-2653 (1994).
46. McIntyre HD, Menazies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR: Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin. Transpl. 9(1), 20-24 (1995).
47. Goffin E, Devogelaer JP, Lalaoui A et al.: Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl. Int. 15(2-3), 73-80 (2002).
48. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S: Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96(1), 213-221 (1989).
49. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE: Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36(4 Pt 1), 895-903 (2002).
50. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B: Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4(1), 1-8 (1984).
51. Shane E, Rivas M, McMahon DJ et al.: Bone loss and turnover after cardiac transplantation. J. Clin. Endocrinol. Metab. 82(5), 1497-1506 (1997).
52. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD: Rapid loss of vertebral mineral density after renal transplantation. N. Engl. J. Med. 325(8), 544-550 (1991).
53. Floreani A: Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC). Gut 50(6), 898; author reply 898-899 (2002).
54. Guo CY, Johnson A, Locke TJ, Eastell R: Mechanisms of bone loss after cardiac transplantation. Bone 22(3), 267-271 (1998).
55. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D: Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am. J. Kidney Dis. 28(1), 105-114 (1996).
56. Sambrook PN, Kelly PJ, Keogh AM et al.: Bone loss after heart transplantation: a prospective study. J. Heart Lung Transplant. 13(1 Pt 1), 116-120 (1994).
57. Berguer DG, Krieg MA, Thiebaud D et al.: Osteoporosis in heart transplant recipients: a longitudinal study. Transplant. Proc. 26(5), 2649-2651 (1994).
58. Van Cleempur J, Daenen W, Nijs J, Geusens P, Dequeker J, Vanhaecke J: Timing and quantification of bone loss in cardiac transplant recipients. Transplant. Int. 8(3), 196-200 (1995).
59. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P: Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur. J. Clin. Invest. 26(7), 549-555 (1996).
60. Shane E, Addesso V, Namerow PB et al.: Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. 350(8), 767-776 (2004).
61. Shane E, Rivas M, Staron RB et al.: Fracture after cardiac transplantation: a prospective longitudinal study. J. Clin. Endocrinol. Metab. 81(5), 1740-1746 (1996).
62. Leidig-Bruckner G, Hosch S, Dodidou P et al.: Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357(9253), 342-347 (2001).
63. Shane E, Papadopoulos A, Staron RB et al.: Bone loss and fracture after lung transplantation. Transplantation 68(2), 220-227 (1999).
64. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ: Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58(8), 912-915 (1994).
65. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(4 Suppl. 3), S1-S201 (2003).
66. American Gastroentorological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 125(3), 937-940 (2003).